Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.

NCT06601010 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06601010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06601010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Recruiting
Start date
September 24, 2024
Completion date
August 31, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer